Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature

BACKGROUND: Despite multidisciplinary treatment approaches, the prognosis for patients with high-grade glioma (HGG) is poor, with a median overall survival (OS) of 14.6 months for glioblastoma multiforme (GB). As high levels of vascular endothelial growth factor A (VEGF) are found in HGG, targeted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeck, Jennifer, Kassubek, Rebecca, Coburger, Jan, Edenhofer, Simone, Schönsteiner, Stefan S., Ludolph, Albert C., Schmitz, Bernd, Engelke, Jens, Mayer-Steinacker, Regine, Lewerenz, Jan, Bullinger, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791550/
https://www.ncbi.nlm.nih.gov/pubmed/29403545
http://dx.doi.org/10.1177/1756285617753597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791550/
https://www.ncbi.nlm.nih.gov/pubmed/29403545
http://dx.doi.org/10.1177/1756285617753597

Ejemplares similares